Millennium Management’s Ocular Therapeutix OCUL Stock Holding History

Millennium Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$288K	Sell	34,006 -3,173,875	-99%	-$30.2M	﹤0.01%	5023
2025 Q4	$38.9M	Sell	3,207,881 -647,825	-17%	-$7.87M	0.02%	987
2025 Q3	$45.1M	Buy	3,855,706 +3,736,560	+3,136%	+$44.7M	0.02%	947
2025 Q2	$1.11M	Buy	+119,146	New	+$933K	﹤0.01%	4329
2025 Q1	–	Sell	-447,237	Closed	-$3.82M	–	6247
2024 Q4	$3.82M	Buy	+447,237	New	+$4.36M	﹤0.01%	3069
2024 Q2	–	Sell	-169,331	Closed	-$1.54M	–	6341
2024 Q1	$1.54M	Sell	169,331 -605,836	-78%	-$4.3M	﹤0.01%	3953
2023 Q4	$3.46M	Buy	775,167 +89,427	+13%	+$264K	﹤0.01%	3117
2023 Q3	$2.15M	Sell	685,740 -1,711,100	-71%	-$7M	﹤0.01%	3486
2023 Q2	$12.4M	Buy	2,396,840 +1,360,285	+131%	+$8.09M	0.01%	1809
2023 Q1	$5.46M	Buy	1,036,555 +959,233	+1,241%	+$4.55M	﹤0.01%	2527
2022 Q4	$217K	Sell	77,322 -123,752	-62%	-$410K	﹤0.01%	5285
2022 Q3	$834K	Sell	201,074 -148,127	-42%	-$746K	﹤0.01%	4491
2022 Q2	$1.4M	Sell	349,201 -386,532	-53%	-$1.46M	﹤0.01%	4051
2022 Q1	$3.64M	Buy	735,733 +443,541	+152%	+$2.46M	﹤0.01%	3286
2021 Q4	$2.04M	Buy	292,192 +10,913	+4%	+$84.7K	﹤0.01%	3766
2021 Q3	$2.81M	Buy	281,279 +266,135	+1,757%	+$2.99M	﹤0.01%	3512
2021 Q2	$215K	Sell	15,144 -179,151	-92%	-$2.72M	﹤0.01%	5969
2021 Q1	$3.19M	Buy	+194,295	New	+$3.74M	﹤0.01%	3071
2020 Q4	–	Sell	-189,007	Closed	-$1.44K	–	5477
2020 Q3	$1.44K	Buy	189,007 +165,570	+706%	+$1.37M	﹤0.01%	2861
2020 Q2	$195K	Sell	23,437 -992,639	-98%	-$6.58M	﹤0.01%	3855
2020 Q1	$5.03M	Buy	1,016,076 +979,183	+2,654%	+$4.83M	0.01%	1334
2019 Q4	$146K	Buy	+36,893	New	+$128K	﹤0.01%	3944
2019 Q1	–	Sell	-210,273	Closed	-$837K	–	4227
2018 Q4	$837K	Buy	210,273 +50,118	+31%	+$276K	﹤0.01%	2671
2018 Q3	$1.1M	Buy	+160,155	New	+$1.01M	﹤0.01%	2819
2018 Q2	–	Sell	-42,369	Closed	-$276K	–	4061
2018 Q1	$276K	Buy	42,369 +20,192	+91%	+$114K	﹤0.01%	3247
2017 Q4	$99K	Buy	22,177 +9,156	+70%	+$46.8K	﹤0.01%	3658
2017 Q3	$80K	Buy	+13,021	New	+$83.8K	﹤0.01%	3377
2017 Q1	–	Sell	-63,370	Closed	-$530K	–	3749
2016 Q4	$530K	Buy	+63,370	New	+$492K	﹤0.01%	2652
2016 Q3	–	Sell	-28,997	Closed	-$144K	–	3510
2016 Q2	$144K	Buy	+28,997	New	+$287K	﹤0.01%	2967
2016 Q1	–	Sell	-276,978	Closed	-$2.6M	–	3544
2015 Q4	$2.6M	Buy	+276,978	New	+$2.99M	0.01%	1769
2014 Q4	–	Sell	-21,559	Closed	-$323K	–	4182
2014 Q3	$323K	Buy	+21,559	New	+$319K	﹤0.01%	3047

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management's OCUL Position: Q1 2026 in Review

Millennium Management reduced its Ocular Therapeutix (OCUL) stake by 99% in Q1 2026, selling an estimated $30.2M and leaving 34,006 shares worth $288K. The position accounts for ﹤0.01% of the portfolio, ranked #5023.

Millennium Management first reported a position in OCUL in Q3 2014 and has held it in 31 quarters since. The position peaked at $45.1M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Millennium Management held 34,006 shares of Ocular Therapeutix worth $288K as of Q1 2026.
Millennium Management sold 3,173,875 Ocular Therapeutix shares in Q1 2026, an estimated $30.2M.
Ocular Therapeutix made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #5023 holding.
Millennium Management first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 31 quarters since.
Millennium Management's Ocular Therapeutix position peaked at $45.1M in Q3 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.